Medication Monitor

Generic Name (Trade Name—Company)
October 1, 2019


FDA approves daratumumab for transplant-eligible multiple myeloma

On September 26, FDA approved daratumumab in combination with bortezomib, thalidomide, and dexamethasone for adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

In clinical trials, the most frequent (≥20%) adverse reactions were infusion reactions, peripheral sensory neuropathy, constipation, asthenia, nausea, peripheral edema, neutropenia, thrombocytopenia, pyrexia, and paresthesia. 

The recommended dosage for this indication is 16 mg/kg actual body weight.

For more informtion, view full prescribing information.